Codexis Stock News

Codexis, Inc. (CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, have s

REDWOOD CITY, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 23) 10X Genomics Inc (NASDAQ: TXG )(reacted to a rulin

Codexis, Inc. (CDXS), a leading protein engineering company, announces a license agreement to provide Roche with Codexis’ EvoT4TM DNA ligase high-performance molecular diagnostic enzyme. This enzym

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investmen

Codexis, Inc. (CDXS), a leading protein engineering company, announces the publication with Merck, known as MSD outside the United States and Canada, of a paper in the prestigious peer-reviewed journa

For many, the main point of investing in the stock market is to achieve spectacular returns. And highest quality...

Q3 2019 Codexis Inc Earnings Call

Equities analysts forecast that Codexis, Inc. (NASDAQ:CDXS) will post $22.82 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates fo

Codexis (CDXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).